Wednesday, July 13, 2011

Australian Securities Exchange Announcement

Investor Update Presentation

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES OR TO U.S. PERSONS

Brisbane, Australia. – ImpediMed Limited (“ImpediMed” or the “Company”) refers shareholders to the attached market update for the Company.

IMPEDIMED LIMITED (IPD) provides the opportunity to listen to an audio broadcast with Mr Greg Brown, Chief Executive Officer and Managing Director about the market update presentation titled “Impedimed Investor Update July 2011 - Greg Brown, CEO”.

To listen, copy the following details into your web browser:


ENDS

For further information contact:

Greg Brown
ImpediMed CEO
T: 61-7-3860-3700
Mobile/Cell: +61408281127

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES

This announcement has been prepared for publication in Australia and New Zealand and may not be distributed or released in the United States. This announcement does not constitute promotion for the use of BIS devices in the United States or in any other jurisdiction in which such device clearance has not been obtained.
ImpediMed Limited
Investor Update
July 2011

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES
Disclaimer

This presentation has been produced by ImpediMed Limited ("ImpediMed") only and may contain forward-looking statements that are based on management’s current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The forward-looking statements contained in this presentation include statements about future financial and operating results, status of our regulatory submissions, coverage, possible or assumed future growth opportunities and risks and uncertainties that could affect ImpediMed’s product and products under development. These statements are not guarantees of future performance, involve certain risks, uncertainties and assumptions that are difficult to predict, and are based upon assumptions as to future events that may not prove accurate. Therefore, actual outcomes and results may differ materially from what is expressed herein. In any forward-looking statement in which ImpediMed expresses an expectation or belief as to future results, such expectation or belief is expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will result or be achieved or accomplished. We are not under any duty to update forward-looking statements unless required by law.

This investor presentation update is not an offer of the sale of securities. ImpediMed and their respective directors, employees, associates, affiliates or agents, make no:

(a) representations or warranties, expressed or implied, in relation to this presentation or the accuracy, reliability or completeness of any information in it or the performance of ImpediMed; and

(b) accept no responsibility for the accuracy or completeness of this presentation and the information contained in it.

This presentation is intended to provide background information only and does not constitute or form part of an offer of securities or a solicitation or invitation to buy or apply for securities, nor may it or any part of it form the basis of, or be relied on in any connection with any contract or commitment whatsoever. The information in this presentation does not take into account the objectives, financial situation or particular needs of any person. Nothing contained in this presentation constitutes investment, legal, tax or other advice. This presentation does not, and does not purport to, contain all the information prospective investors in ImpediMed would desire or require in reaching an investment decision.

To the maximum extent permitted by law, none of ImpediMed, their officers, directors, employees, associates, affiliates or agents, nor any other person accepts any liability for any loss, claim, damages, costs or expenses of whatever nature (whether or not foreseeable), including, without limitation, any liability arising from fault or negligence on the part of any of them or any other person, for any loss arising from the use of this presentation or its contents or otherwise arising in connection with it or any errors or omissions in it.

The distribution of this presentation in jurisdictions outside Australia may be restricted by law and you should observe any such restrictions. This presentation has not been filed, lodged, registered or approved in any jurisdiction and recipients of this presentation should keep themselves informed of and comply with and observe all applicable legal and regulatory requirements. This presentation is made only to sophisticated or professional investors under the Corporations Act.
Clinical Assessment of Lymphedema

- High incidence
- Underserved / early Dx
- Early Dx / prevention

- IP hurdles in place
- First FDA clearance

- Support and advocacy
- Clinical Standard - NAPBC

- First mover advantage and category III code
- Code, payment and building coverage – critical to drive sales
Reimbursement – Critical to drive business model

1. Coding
   - CPT procedure codes
   - ICD-9-CM diagnosis and procedure codes
   - HCPCS drug, device and durable medical equipment codes

2. Coverage
   - National vs. Regional vs. Local coverage policies
   - Blue Cross and Blue Shield Technology policies
   - Private insurers (National/Regional) and managed care coverage policies

3. Payment
   - Outpatient hospital Ambulatory Payment Classification (APC) and pass-through payment
   - Physician & diagnostic test payment under the resource-based, relative value schedule (RBRVS)
   - Durable Medical Equipment payment under DMERC fee schedules

   **Market metrics for showing effective reimbursement – coding, payment and coverage**
   - The best metric is sales - moving forward placements and revenue per placement important
   - Early with a new code it is useful to have a metric to show traction, the options are
     - **Medical policy – covered lives**
       - Medical policy - no policy, experimental/investigational, or medically necessary
       - Less likely to double count lives, but can underestimate coverage
       - Coverage can still occur without medical policy
     - **Managed Care – Membership – can show coverage without policy, double/triple counts lives**
Reimbursement Update

1. L-Dex testing coverage building in the market
   - Coverage occurring – Explanation of Benefits (EOB’s) showing reimbursement of CPT 0239T
   - Examples of major private payers covering at local levels - only seen in certain states at present
   - Payment in the range supported by the economic model presented in 2010

2. Covered lives metric - medical policy
   - Federal plans – first 12 million covered lives announced
   - Advancing private payers – UPMC, & Humana (ACO)
   - ACO’s and coverage specific policy – working both avenues now

3. Membership metric - managed Care
   - 5 PPO signed contracts in place for handling reimbursement claims
   - Beech Street – Viant (BSV) – covering some claims
     ✓ BSV is an at risk PPO with 16 million members - Covering L-Dex clients at a percentage of billed charges or contracted default percentage discount when billing CPT 0239T

4. Key obstacles for building covered lives – medical policy
   - Need clinical outcomes data for L-Dex over present conventional methods – key to health economics
     ✓ A number of surgeons are coordinating to publish case study data
     ✓ Randomised control trial underway to water displacement
   - Medical Directors - clear lack of understanding to the limitations of conventional methods
     ✓ Referenced arguments listed on website; plus review article expected
The L-Dex U400 will be evaluated under the criteria stated in the definition of medical necessity in each contract. A typical example of a contractual definition of “medical necessity” is as follows:

1. Appropriate to prevent, diagnose, or treat your condition, illness or injury;
2. Consistent with standards of good medical practice in the United States;
3. Not primarily for the personal comfort or convenience of the patient, the family or the provider;
4. Not part of or associated with scholastic education or vocational training or the patient; and
5. In the case of inpatient care, can only be provided safely in the acute inpatient hospital setting.

Criteria 1, 2 and 3 above are most relevant for the purposes of the L-Dex U400.

May 2011 – US Clinical standard (NAPBC/NLN) important for building support for criteria number 2

Obama-care changes – 1) Automatic Enrollment in Employer Health Plans, 2) Coverage of Adult Children (up to age 26), 3) Lifetime limits on dollar amount of coverage not permitted, 4) Health plans must provide coverage, without cost-sharing, for certain preventive services & immunizations, 5) Insurance denial of coverage based on a pre-existing condition is not permitted for children under age 19;

- Hyper-changing environment continues for payers and cost impact still to be fully recognised
- Accountable care and preventative care programs growing in significance
- Payers reluctant to change policies – higher level of evidence required at this point
- Likely to see coverage without policy while market settles down
Review of other recent progress

1. Placement Update
   - 142 L-Dex devices placed in the market - April 2010 total was 121 – increase of 21

2. Prominent Clinical Centers now using
   - UPMC Pittsburg /Columbia Presbyterian Hospital NYC
   - William Beaumont Hospital – significant percentage of all breast patients in Michigan
   - Lynn Regional Miami – large breast cancer clinic in Florida

3. Multi-site Users
   - 21st Century Oncology - signed 4 agreements with 21st Century for a system-wide test
   - US Oncology first placement – large Breast center in Dallas

4. Stanford Registry progressing and on the timeline

5. NAPBC/NLN – Clinical Standard 2.15 – First clinical standard/guidelines

6. Avon Foundation for Women Lymphedema event in NYC – supported by Avon, LRF, NLN
   - White paper to publish in the coming months
   - Calls for more clinical guidelines from governing societies

7. Several key publications expected
   - Patient case studies – clinical outcomes data from key users
   - Key trial 5 year follow up data and independent economic data
### Targeted News Flow – Calendar year 2011 / 2012

<table>
<thead>
<tr>
<th>News Flow Pipeline:</th>
<th>1H11</th>
<th>2H11</th>
<th>1H12</th>
<th>2H12</th>
</tr>
</thead>
<tbody>
<tr>
<td>Announcement of first covered lives</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Announcement of 20 million covered lives</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stanford registry launch and roll out</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Publication on health economic paper</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Announcement clinical guidelines</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Announcement of 50 million covered lives</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Key outcomes publication on BIS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unilateral Limb (arm &amp; leg) FDA - U400</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>250 placement of L-Dex devices</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCD CED Stanford resubmission</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>